JP2009159869A - 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法 - Google Patents

癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法 Download PDF

Info

Publication number
JP2009159869A
JP2009159869A JP2007341430A JP2007341430A JP2009159869A JP 2009159869 A JP2009159869 A JP 2009159869A JP 2007341430 A JP2007341430 A JP 2007341430A JP 2007341430 A JP2007341430 A JP 2007341430A JP 2009159869 A JP2009159869 A JP 2009159869A
Authority
JP
Japan
Prior art keywords
nucleotide sequence
znf143
cancer
polynucleotide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007341430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009159869A5 (enExample
Inventor
Kimitoshi Kono
公俊 河野
Hirohito Izumi
弘人 和泉
Yasuyuki Sasakuri
靖之 笹栗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Occupational and Environmental Health Japan
Original Assignee
University of Occupational and Environmental Health Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Occupational and Environmental Health Japan filed Critical University of Occupational and Environmental Health Japan
Priority to JP2007341430A priority Critical patent/JP2009159869A/ja
Priority to PCT/JP2008/073817 priority patent/WO2009084668A1/ja
Priority to EP08869206A priority patent/EP2246069A4/en
Priority to US12/810,696 priority patent/US8580758B2/en
Publication of JP2009159869A publication Critical patent/JP2009159869A/ja
Publication of JP2009159869A5 publication Critical patent/JP2009159869A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
JP2007341430A 2007-12-28 2007-12-28 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法 Pending JP2009159869A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007341430A JP2009159869A (ja) 2007-12-28 2007-12-28 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
PCT/JP2008/073817 WO2009084668A1 (ja) 2007-12-28 2008-12-26 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
EP08869206A EP2246069A4 (en) 2007-12-28 2008-12-26 METHOD FOR INHIBITING CANCER CELL PROGRAMMING, PROLIFERATION INHIBITOR AND SCREENING METHOD
US12/810,696 US8580758B2 (en) 2007-12-28 2008-12-26 Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007341430A JP2009159869A (ja) 2007-12-28 2007-12-28 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法

Publications (2)

Publication Number Publication Date
JP2009159869A true JP2009159869A (ja) 2009-07-23
JP2009159869A5 JP2009159869A5 (enExample) 2011-02-03

Family

ID=40824381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007341430A Pending JP2009159869A (ja) 2007-12-28 2007-12-28 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法

Country Status (4)

Country Link
US (1) US8580758B2 (enExample)
EP (1) EP2246069A4 (enExample)
JP (1) JP2009159869A (enExample)
WO (1) WO2009084668A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004556A1 (ja) 2009-07-06 2011-01-13 株式会社フジクラ 貫通配線基板及びその製造方法
WO2019093502A1 (ja) * 2017-11-09 2019-05-16 国立大学法人 東京医科歯科大学 がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
US12066429B2 (en) 2016-05-10 2024-08-20 National University Corporation Tokyo Medical And Dental University Method for inhibiting the expression of inflammation promoting factors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536420A (ja) * 1999-02-10 2002-10-29 パンジーン・コーポレイション Ｒａｄ５１の新規のアンチセンス阻害
JP2005527553A (ja) * 2002-03-29 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 自己免疫疾患の治療におけるスタチン類および他の自己免疫調節剤の利用
JP2006506964A (ja) * 2002-06-12 2006-03-02 リサーチ　ディベロップメント　ファンデーション 治療剤としての免疫毒素及びその利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228337D0 (en) * 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536420A (ja) * 1999-02-10 2002-10-29 パンジーン・コーポレイション Ｒａｄ５１の新規のアンチセンス阻害
JP2005527553A (ja) * 2002-03-29 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 自己免疫疾患の治療におけるスタチン類および他の自己免疫調節剤の利用
JP2006506964A (ja) * 2002-06-12 2006-03-02 リサーチ　ディベロップメント　ファンデーション 治療剤としての免疫毒素及びその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009004697; ＷＡＫＡＳＵＧＩ，Ｔ．　ｅｔ　ａｌ: 'ＺＮＦ１４３　ｉｎｔｅｒａｃｔｓ　ｗｉｔｈ　ｐ７３　ａｎｄ　ｉｓ　ｉｎｖｏｌｖｅｄ　ｉｎ　ｃｉｓｐｌａｔｉｎ　ｒｅｓｉｓｔａｎｃｅ　ｔｈｒｏｕｇｈ　ｔｈｅ　ｔｒａｎｓｃｒｉｐｔｉｏｎａｌ　ｒｅｇｕｌａ' Ｏｎｃｏｇｅｎｅ Ｖｏｌ．２６，　Ｎｏ．３６, 20070212, ｐ．５１９４-２０３ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004556A1 (ja) 2009-07-06 2011-01-13 株式会社フジクラ 貫通配線基板及びその製造方法
US12066429B2 (en) 2016-05-10 2024-08-20 National University Corporation Tokyo Medical And Dental University Method for inhibiting the expression of inflammation promoting factors
WO2019093502A1 (ja) * 2017-11-09 2019-05-16 国立大学法人 東京医科歯科大学 がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
JPWO2019093502A1 (ja) * 2017-11-09 2021-02-25 国立大学法人 東京医科歯科大学 がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
JP7376873B2 (ja) 2017-11-09 2023-11-09 国立大学法人 東京医科歯科大学 がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
IL274456B1 (en) * 2017-11-09 2024-04-01 Univ Nat Corp Tokyo Medical & Dental Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
IL274456B2 (en) * 2017-11-09 2024-08-01 Univ Nat Corp Tokyo Medical & Dental Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
US12253515B2 (en) 2017-11-09 2025-03-18 National University Corporation Tokyo Medical And Dental University Method for inhibiting the expression of cancer-promoting factors

Also Published As

Publication number Publication date
US8580758B2 (en) 2013-11-12
US20100280101A1 (en) 2010-11-04
WO2009084668A1 (ja) 2009-07-09
EP2246069A1 (en) 2010-11-03
EP2246069A4 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
US12421514B2 (en) Methods for diagnosing and treating metastatic cancer
JP2023098926A (ja) Ｔｕｔ４／７発現調節因子を含む癌予防又は治療用薬学的組成物
CN103380214B (zh) 用于治疗脑肿瘤的支链氨基转移酶-1(bcat1)抑制剂
US20090074785A1 (en) Compositions and methods for treatment of colorectal cancer
JPWO2017195809A1 (ja) 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
JP7175526B2 (ja) 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価
US8580758B2 (en) Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method
WO2011061194A1 (en) Inhibitors of centrosomal clustering
JP6653120B2 (ja) Ｉｋａｒｏｓ阻害に基づく抗炎症薬
JP5697010B2 (ja) 腫瘍新生血管血管内皮細胞の新しいバイオマーカーとそれを標的とした癌治療薬
JP6839707B2 (ja) Ｇｐｒ１６０を過剰発現する癌の予防、診断および治療
JP2008263851A (ja) 熱射病の治療ターゲット
WO2010024405A1 (ja) Ｉ型ｉｆｎの産生阻害剤、及びその探索方法
JP5511135B2 (ja) 癌を治療するための材料および方法
WO2008069621A1 (en) Novel use of mig12 and oip5 genes
JPWO2008102777A1 (ja) インスリン抵抗性改善剤
KR100986465B1 (ko) Ｏｉｐ５ 유전자의 신규한 용도
WO2014095916A1 (en) Ninjurin-1 as therapeutic target for brain tumor
KR20230045386A (ko) miR-4487를 유효성분으로 함유하는 항암제 민감성 증진용 조성물
JP2009268381A (ja) 癌特異的酢酸代謝を標的とした癌バイオマーカー・検査方法・治療剤

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121218

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130402